
Teva’s CEO shares ‘Pivot to Growth’ progress
The Top Line
00:00
Transforming to Biopharma: Teva's Growth Journey
This chapter outlines Teva's strategic transformation towards becoming a biopharma company, aiming for a $700 million cost reduction through modernization and resource reallocation. It highlights the company's recent growth after a five-year sales decline, with ambitious plans for innovative products and an emphasis on strengthening product pipelines. The speaker expresses optimism for the future, acknowledging the dedication of employees in this significant transition and the focus on sustained profitability and growth.
Transcript
Play full episode